TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22510424

Group type: EXPERIMENTAL
Intervention: Lixivaptan 100 mg once daily
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study: 21037433

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (oxaliplatin- or irinotecan-based, at least 3 cycles)
Number of subjects: 1471

Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy
Number of subjects: 1471

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy
Number of subjects: 1471

Group type: COMPARATOR
Intervention: Control group (S)
Number of subjects: 1471

Group type: COMPARATOR
Intervention: Control group (CS)
Number of subjects: 1471
Study: 17960520

Group type: EXPERIMENTAL
Intervention: Intrahospital supervised exercise training (3 weekly sessions of resistance and aerobic training for 8 weeks)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intrahospital supervised exercise training
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (age and gender-matched healthy children)
Number of subjects: 8
Study: 15663607

Group type: EXPERIMENTAL
Intervention: Zolmitriptan 5 mg nasal spray
Number of subjects: 912

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 912
Study: 14628180

Group type: EXPERIMENTAL
Intervention: Preparing for Parenthood (PFP) intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Qualitative study of PFP intervention
Number of subjects: 0
Study: 10584996

Group type: EXPERIMENTAL
Intervention: Nadroparin administered by the venous line
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nadroparin administered by the arterial line
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nadroparin with part of the dose added to the priming solution
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nadroparin administration (both routes)
Number of subjects: 12
Study: 8712133

Group type: EXPERIMENTAL
Intervention: Baseline fibrinogen concentration > or = 300 mg/dl
Number of subjects: 1473

Group type: EXPERIMENTAL
Intervention: Higher fibrinogen concentrations in patients with spontaneous ischemia
Number of subjects: 1473

Group type: EXPERIMENTAL
Intervention: Combined unsatisfactory outcome of death, myocardial infarction, and spontaneous ischemia
Number of subjects: 1473
Study: 1726199

Group type: EXPERIMENTAL
Intervention: Screening group (alpha‐fetoprotein (AFP) screening every six months)
Number of subjects: 3958

Group type: COMPARATOR
Intervention: Non-screening group
Number of subjects: 3958

Group type: EXPERIMENTAL
Intervention: Screening survey among males aged 30‐59 years with negative HBsAg (once a year)
Number of subjects: 3958

Group type: EXPERIMENTAL
Intervention: Screening group (alpha‐fetoprotein (AFP) screening)
Number of subjects: 3958

Group type: COMPARATOR
Intervention: Out-patients (no screening)
Number of subjects: 3958
Study: 6354929

Group type: EXPERIMENTAL
Intervention: Captopril 12.5 mg t.i.d.
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Captopril 25 mg t.i.d.
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Captopril 37.5 mg b.i.d.
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg t.i.d.
Number of subjects: 140

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (H) alone
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Captopril plus Hydrochlorothiazide (C plus H) 12.5 mg
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Captopril plus Hydrochlorothiazide (C plus H) 25 mg
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Captopril plus Hydrochlorothiazide (C plus H) 37.5 mg
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Captopril plus Hydrochlorothiazide (C plus H) 50 mg
Number of subjects: 140
Study: 30683103

Group type: EXPERIMENTAL
Intervention: Vaginal gel and oral tablets for HIV prevention
Number of subjects: 171
Study: 27734104

Group type: EXPERIMENTAL
Intervention: hyperinsulinaemic hypoglycaemia (HH; i.v. bolus of 0.1 U/kg insulin)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: hyperinsulinaemic euglycaemia (HE; i.v. bolus of 0.1 U/kg insulin and 20% glucose)
Number of subjects: 9

Group type: COMPARATOR
Intervention: saline control
Number of subjects: 9
Study: 27213436

Group type: EXPERIMENTAL
Intervention: Decreased total water intake (TWI) for HIGH group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Increased total water intake (TWI) for LOW group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both HIGH and LOW groups during the intervention
Number of subjects: 120
Study: 24561057

Group type: EXPERIMENTAL
Intervention: rpMS
Number of subjects: 66

Group type: COMPARATOR
Intervention: sham stimulation
Number of subjects: 66
Study: 21852153

Group type: EXPERIMENTAL
Intervention: Atherothrombotic infarction
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Lacunar stroke
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Cardioembolic stroke
Number of subjects: 49

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 49
Study: 20852275

Group type: EXPERIMENTAL
Intervention: Prednisone prophylaxis
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Age over 8 years at onset
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Abdominal pain
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Recurrence of HSP disease
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Two or three risk factors
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Urine dipstick testing
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Follow-up for nephritis
Number of subjects: 223
Study: 17480153

Group type: EXPERIMENTAL
Intervention: Group I (25-26 degrees C)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Group II (32-33 degrees C)
Number of subjects: 15
Study: 15227557

Group type: EXPERIMENTAL
Intervention: Sequential Multi Layered Perceptron (SMLP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Targeted screening (impaired glucose tolerance test) combined with SMLP
Number of subjects: 0
Study: 11573751

Group type: EXPERIMENTAL
Intervention: Goal setting
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Self-monitoring
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Goal setting and self-monitoring
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Goal setting only
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Goal setting and goal setting and self‐monitoring
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group (no goal setting and no self‐monitoring)
Number of subjects: 113
Study: 9757874

Group type: EXPERIMENTAL
Intervention: Breast-feeding practices
Number of subjects: 4118
Study: 7949205

Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (500 mg daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (lower dose without hydrocortisone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (lower dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (initial high dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Testololactone
Number of subjects: 0
Study: 3266277

Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field (PEMF) treatment
Number of subjects: 11
Study: 31843973

Group type: EXPERIMENTAL
Intervention: Married or partnered patients
Number of subjects: 367

Group type: COMPARATOR
Intervention: Single patients
Number of subjects: 367
Study: 31115060

Group type: EXPERIMENTAL
Intervention: High-fidelity simulation intervention
Number of subjects: 107
Study: 27260004

Group type: EXPERIMENTAL
Intervention: SIT+nitrate (NIT)
Number of subjects: 27

Group type: COMPARATOR
Intervention: SIT+placebo (PLA)
Number of subjects: 27
Study: 26115578

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) nasal aerosol at 80 μg/day
Number of subjects: 547

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 547
Study: 23522911

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (aRT) 60Gy
Number of subjects: 385

Group type: COMPARATOR
Intervention: Wait and see
Number of subjects: 385
Study: 21999489

Group type: EXPERIMENTAL
Intervention: Escitalopram (10 mg)
Number of subjects: 79
Study: 19595295

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT) and Prolonged Exposure (PE)
Number of subjects: 145
Study: 17010995

Group type: EXPERIMENTAL
Intervention: CBZ plus FEWP (n=96)
Number of subjects: 188

Group type: COMPARATOR
Intervention: CBZ plus placebo (n=92)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: FEWP monotherapy (36 g/day, n=86)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Placebo (n=63)
Number of subjects: 188
Study: 15095554

Group type: EXPERIMENTAL
Intervention: TPA + TCD (2 hours of continuous monitoring with TCD)
Number of subjects: 126

Group type: COMPARATOR
Intervention: TPA (standard 0.9 mg/kg TPA therapy)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: TPA + TCD
Number of subjects: 126

Group type: COMPARATOR
Intervention: TPA
Number of subjects: 126
Study: 11216320

Group type: EXPERIMENTAL
Intervention: Sentence span task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Arithmetic verification with recall of presented words
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple resource model
Number of subjects: 0
Study: 9825384

Group type: EXPERIMENTAL
Intervention: High-intensity physical training on land
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: High-intensity physical training in water
Number of subjects: 32

Group type: COMPARATOR
Intervention: Both training forms (land and water)
Number of subjects: 32
Study: 7640924

Group type: EXPERIMENTAL
Intervention: iomeprol 350 mg I ml‐1
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: iohexol 350 mg I ml‐1
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: iopamidol 370 mg I ml‐1
Number of subjects: 90
Study: 2520297

Group type: EXPERIMENTAL
Intervention: Daily vitamin‐mineral supplement containing 2 or 3 mg of vitamin B6 for 9 days before surgery and multivitamin supplement containing 0.4, 0.8 or 2 mg of vitamin B6 for 3 months postoperatively
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 2 mg of supplemental vitamin B6 per day during the fourth month
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Preoperative plasma PLP levels
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Rate of weight loss
Number of subjects: 15

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 15
Study: 335968

Group type: EXPERIMENTAL
Intervention: Cefoxitin
Number of subjects: 143

Group type: COMPARATOR
Intervention: Cephalothin
Number of subjects: 143
Study: 31246878

Group type: EXPERIMENTAL
Intervention: BWL therapy (30-minute exposure to waking white light enriched with blue for 4 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: N-BWL (no light therapy)
Number of subjects: 0
Study: 31382201

Group type: EXPERIMENTAL
Intervention: Higher CBD and lower price
Number of subjects: 2400

Group type: EXPERIMENTAL
Intervention: Higher THC
Number of subjects: 2400

Group type: EXPERIMENTAL
Intervention: Graphic warning on drugged driving
Number of subjects: 2400

Group type: EXPERIMENTAL
Intervention: Text warning message
Number of subjects: 2400

Group type: EXPERIMENTAL
Intervention: FDA disapproval disclaimer
Number of subjects: 2400

Group type: EXPERIMENTAL
Intervention: Price
Number of subjects: 2400

Group type: EXPERIMENTAL
Intervention: CBD
Number of subjects: 2400
Study: 28402191

Group type: EXPERIMENTAL
Intervention: Interval running on grass surface
Number of subjects: 10

Group type: COMPARATOR
Intervention: Interval running on sand surface
Number of subjects: 10
Study: 25432966

Group type: EXPERIMENTAL
Intervention: Probiotics treatment
Number of subjects: 260

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study: 23958818

Group type: EXPERIMENTAL
Intervention: Intravenous hydromorphone
Number of subjects: 50
Study: 22076901

Group type: EXPERIMENTAL
Intervention: Manual acupuncture (10 sessions at the rate of three sessions per week)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 31
Study: 19302739

Group type: EXPERIMENTAL
Intervention: Laparoscopic assisted vaginal hysterectomy (LAVH)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Total vaginal hysterectomy (TVH)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Total abdominal hysterectomy (TAH)
Number of subjects: 101
Study: 17456523

Group type: EXPERIMENTAL
Intervention: Recently diagnosed active RA patients (no prior DMARDs or corticosteroids)
Number of subjects: 381
Study: 14699198

Group type: EXPERIMENTAL
Intervention: Multiple-family group treatment
Number of subjects: 97

Group type: COMPARATOR
Intervention: Standard psychiatric outpatient care
Number of subjects: 97
Study: 11434080

Group type: EXPERIMENTAL
Intervention: Educational activities tailored to local needs including surgeon study groups, primary care continuing medical education conferences, administrative consensus processes, videodisc-aided patient decision making, surgical outcomes management, and generalist academic detailing over a 30-month period.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control communities (not specified in detail).
Number of subjects: 10
Study: 10993585

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) therapy
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 7860811

Group type: EXPERIMENTAL
Intervention: Dissuasion interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Various dissuasion methods
Number of subjects: 0
Study: 2173435

Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg once daily (4000 anti Xa U)
Number of subjects: 583

Group type: COMPARATOR
Intervention: Unfractionated calcic Heparin (5000 U.I. every eight hours)
Number of subjects: 583

Group type: COMPARATOR
Intervention: Placebo (as referenced from Turpie, Levine, et al 1986)
Number of subjects: 583
Study: 73013

Group type: EXPERIMENTAL
Intervention: Mixture of A.M.L. cells and B.C.G. given on 4 occasions early in remission
Number of subjects: 30

Group type: COMPARATOR
Intervention: Immunotherapy with killed allogeneic A.M.L. cells and Glaxo B.C.G. (Control group)
Number of subjects: 30
Study: 30865109

Group type: EXPERIMENTAL
Intervention: Classical endotracheal intubation
Number of subjects: 61

Group type: COMPARATOR
Intervention: Baska Mask (LMA)
Number of subjects: 61
Study: 28225297

Group type: EXPERIMENTAL
Intervention: Cinitapride (CIN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simethicone (co-administered with CIN)
Number of subjects: 0
Study: 26316154

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical posterior tibial nerve stimulation
Number of subjects: 73

Group type: COMPARATOR
Intervention: Lateral internal sphincterotomy
Number of subjects: 73
Study: 22472904

Group type: EXPERIMENTAL
Intervention: Night-shift group on days off
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Night-shift group on 4th consecutive day off
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Night-shift group after 4th consecutive day off
Number of subjects: 62

Group type: COMPARATOR
Intervention: Day-shift group
Number of subjects: 62
Study: 21723989

Group type: EXPERIMENTAL
Intervention: 4-implant bar attachment
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2-implant bar attachment
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2 independent ball attachments
Number of subjects: 30

Group type: COMPARATOR
Intervention: Criterion-based retention scores for all treatments
Number of subjects: 30

Group type: COMPARATOR
Intervention: Force gauge and criterion-based prosthesis stability measurements
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: O-ring treatment
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 4-implant bar treatment
Number of subjects: 30
Study: 19403468

Group type: EXPERIMENTAL
Intervention: Zolpidem at 0.25 mg/kg per day (maximum of 10 mg/day)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Zolpidem
Number of subjects: 201
Study: 16146698

Group type: EXPERIMENTAL
Intervention: Electromyographic activity recorded from the rectus femoris (RF) before exercise, at half-time and immediately after the 90-min exercise protocol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Electromyographic activity recorded from the biceps femoris (BF) before exercise, at half-time and immediately after the 90-min exercise protocol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Electromyographic activity recorded from the tibialis anterior (TA) before exercise, at half-time and immediately after the 90-min exercise protocol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Electromyographic activity recorded from the gastrocnemius (GC) before exercise, at half-time and immediately after the 90-min exercise protocol
Number of subjects: 10
Study: 16625136

Group type: EXPERIMENTAL
Intervention: Intervention group (n=130)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Control group (n=100)
Number of subjects: 230
Study: 12765594

Group type: EXPERIMENTAL
Intervention: Bemiparin (heparin of low molecular weight), injected subcutaneously at 3500 IU/day for the first 10 days and 2500 IU/day up to 90 days
Number of subjects: 42

Group type: COMPARATOR
Intervention: Physiological serum injected subcutaneously
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Bemiparin
Number of subjects: 42
Study: 10490798

Group type: EXPERIMENTAL
Intervention: 189 bp homozygotes
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: 189 bp heterozygotes
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: non-189 bp carriers
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: IGF-1 marker
Number of subjects: 502
Study: 8951932

Group type: EXPERIMENTAL
Intervention: Bosentan 250 mg i.v.
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 1955637

Group type: EXPERIMENTAL
Intervention: SMX168-poly-L-tyrosine skin test reagent
Number of subjects: 50

Group type: COMPARATOR
Intervention: SMX-tyrosine (monovalent reagent)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: RAST assessment
Number of subjects: 50
Study: 7048919

Group type: EXPERIMENTAL
Intervention: 5 percent topical acyclovir ointment
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo, polyethylene glycol (PEG)
Number of subjects: 180
Study: 31984762

Group type: EXPERIMENTAL
Intervention: Annual contact group (phone calls at baseline, 6 months, and annually through 3 years)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Baseline contact group (phone call at baseline only)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Participants successfully contacted at baseline
Number of subjects: 305

Group type: COMPARATOR
Intervention: Participants not contacted successfully at baseline
Number of subjects: 305
Study: 29233473

Group type: EXPERIMENTAL
Intervention: Intracranial electrodes (depth and/or strip leads) implanted for brain-responsive stimulation
Number of subjects: 121
Study: 27527848

Group type: EXPERIMENTAL
Intervention: iGlarLixi
Number of subjects: 1170

Group type: COMPARATOR
Intervention: iGlar
Number of subjects: 1170

Group type: COMPARATOR
Intervention: Lixi
Number of subjects: 1170
Study: 25551475

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) treatment
Number of subjects: 61

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 61
Study: 23850491

Group type: EXPERIMENTAL
Intervention: Sitimagene ceradenovec (1×10^12 viral particles) followed by ganciclovir (5 mg/kg intravenously twice a day) in addition to standard care
Number of subjects: 250

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Sitimagene ceradenovec and ganciclovir
Number of subjects: 250
Study: 20965380

Group type: EXPERIMENTAL
Intervention: Participation in physical activities as reported by 8th-grade girls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participation in organized programs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physical activity trends from 6th to 8th grade
Number of subjects: 0
Study: 19052243

Group type: EXPERIMENTAL
Intervention: Protein supplementation (10% protein) for 21 days
Number of subjects: 42

Group type: COMPARATOR
Intervention: Spontaneous diet only (control group)
Number of subjects: 42
Study: 16415304

Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg daily)
Number of subjects: 866

Group type: EXPERIMENTAL
Intervention: CEE/MPA (0.625/2.5 mg daily)
Number of subjects: 866

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 866
Study: 12571649

Group type: EXPERIMENTAL
Intervention: Advice to eat two portions of oily fish each week or take three fish oil capsules daily
Number of subjects: 3114

Group type: EXPERIMENTAL
Intervention: Advice to eat more fruit, vegetables, and oats
Number of subjects: 3114

Group type: EXPERIMENTAL
Intervention: Both types of dietary advice (oily fish and fruit)
Number of subjects: 3114

Group type: COMPARATOR
Intervention: No specific dietary advice
Number of subjects: 3114
Study: 10618299

Group type: EXPERIMENTAL
Intervention: (32)P radioactive beta-emitting stents with activity level of 0.75 to 3.0 microCi (group 1)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: (32)P radioactive beta-emitting stents with activity level of 3.0 to 6.0 microCi (group 2)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: (32)P radioactive beta-emitting stents with activity level of 6.0 to 12.0 microCi (group 3)
Number of subjects: 82
Study: 9199864

Group type: EXPERIMENTAL
Intervention: Electrical stimulation (ES) treatment for two weeks
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (rehabilitation only) for two weeks
Number of subjects: 11
Study: 8260078

Group type: EXPERIMENTAL
Intervention: Doppler ultrasound intervention
Number of subjects: 4235

Group type: COMPARATOR
Intervention: Standard obstetric management (control)
Number of subjects: 4235
Study: 3978008

Group type: EXPERIMENTAL
Intervention: 0.0625% bupivacaine 6.25 mg h‐1 infusion
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine 10 ml h‐1 infusion
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine 12.5 mg h‐1 infusion
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine 18.75 mg h‐1 infusion
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (no infusion)
Number of subjects: 98
Study: 29392869

Group type: EXPERIMENTAL
Intervention: Pulsed Dye Laser (PDL) combined with fractional CO2 laser
Number of subjects: 56

Group type: COMPARATOR
Intervention: 595 nm PDL
Number of subjects: 56
Study: 27784622

Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham KT (Control)
Number of subjects: 30